Resource Summary Report

Generated by NIF on Jul 28, 2026

Brilliant Violet 510(TM) anti-human CD19

RRID:AB_2561668
Type: Antibody

Proper Citation

BioLegend Cat# 302242, RRID:AB_2561668

Antibody Information

URL: http://antibodyregistry.org/AB_2561668

Proper Citation: BioLegend Cat# 302242, RRID:AB_2561668

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_2561668

Vendor: BioLegend

Catalog Number: 302242

Alternative Catalog Numbers: 302241

Record Creation Time: 20250820T003622+0000

Record Last Update: 20250820T084321+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-human CD19.

No alerts have been found for Brilliant Violet 510(TM) anti-human CD19.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Rao VN, et al. (2025) Clonotype-enriched somatic hypermutations drive affinity maturation of a public human antibody targeting an occluded sarbecovirus epitope. Cell reports, 44(8), 116122.

Arbués A, et al. (2025) Soluble immune mediators orchestrate protective in vitro granulomatous responses across Mycobacterium tuberculosis complex lineages. eLife, 13.

Conti A, et al. (2025) Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells. Cell reports. Medicine, 6(6), 102157.

Van Laethem JL, et al. (2025) CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Cell reports. Medicine, 6(10), 102407.

Chu Q, et al. (2025) Efficient boosting of Omicron-reactive memory B cells after breakthrough infection protects from repeated exposure. iScience, 28(4), 112278.

Martínez-Balboa Y, et al. (2025) Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine. iScience, 28(8), 113167.

Della Volpe L, et al. (2025) Protocol for optimizing culture conditions for ex vivo activation during CRISPR-Cas9 gene editing in human hematopoietic stem and progenitor cells. STAR protocols, 6(2), 103722.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. Cell reports. Medicine, 6(8), 102257.

Dingus J, et al. (2025) Affinity maturation and light-chain-mediated paratope diversification anticipates viral evolution. Cell reports, 45(1), 116800.

Pelletier AN, et al. (2024) A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine. Cell reports, 43(7), 114370.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. Cell reports, 44(1), 115102.

Müller TR, et al. (2024) Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. Cell host & microbe, 32(2), 156.

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. Cell reports. Medicine, 5(11), 101823.

Padoan B, et al. (2024) NKp44/HLA-DP-dependent regulation of CD8 effector T cells by NK cells. Cell reports, 43(4), 114089.

Adamo S, et al. (2023) Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. Cell host & microbe, 31(6), 928.

Touizer E, et al. (2023) Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. iScience, 26(1), 105862.

Nellore A, et al. (2023) A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans. Immunity, 56(4), 847.

Kirosingh AS, et al. (2023) Malaria-specific Type 1 regulatory T cells are more abundant in first pregnancies and associated with placental malaria. EBioMedicine, 95, 104772.

van der Ploeg K, et al. (2022) TNF-?+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell reports. Medicine, 3(6), 100640.

Gao Y, et al. (2022) Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity, 55(9), 1732.